NASDAQ:VTVT vTv Therapeutics Q3 2024 Earnings Results & Report $31.18 +1.10 (+3.66%) Closing price 04:00 PM EasternExtended Trading$31.14 -0.04 (-0.11%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. vTv Therapeutics reported Q3 2024 earnings on November 12, 2024. The company reported EPS of -$0.88. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2024Report DateNovember 12, 2024TimeAfter Market ClosesConference Call7:00 AM ET vTv Therapeutics EPS ResultsActual EPS-$0.88Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AEPS Beat Rate3 of last 7 quartersvTv Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsvTv Therapeutics' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) vTv Therapeutics Q3 2024 Earnings FAQ Did vTv Therapeutics beat earnings estimates for Q3 2024? vTv Therapeutics (NASDAQ:VTVT) reported earnings of -$0.88 per share for Q3 2024. The report was announced on Tuesday, November 12, 2024. When is vTv Therapeutics' next earnings date? vTv Therapeutics' next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for vTv Therapeutics on the company's earnings history page. vTv Therapeutics Earnings HeadlinesvTv Therapeutics stock jumps on FDA orphan drug statusOctober 8 at 4:49 PM | uk.finance.yahoo.comAnalysts Conflicted on These Healthcare Names: vTv Therapeutics (VTVT) and CSL (OtherCMXHF)October 8 at 6:47 AM | theglobeandmail.comThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.October 9 at 1:00 AM | Reagan Gold Group (Ad)VTv's HPPD Receives FDA Orphan Drug Status For Sickle Cell DiseaseOctober 8 at 6:47 AM | rttnews.comContrasting Milestone Pharmaceuticals (NASDAQ:MIST) and vTv Therapeutics (NASDAQ:VTVT)October 8 at 2:15 AM | americanbankingnews.comvTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell DiseaseOctober 7 at 4:01 PM | globenewswire.comSee More vTv Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like vTv Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on vTv Therapeutics and other key companies, straight to your email. Email Address About vTv TherapeuticsvTv Therapeutics (NASDAQ:VTVT), Inc. (NASDAQ: VTVT) is a clinical-stage biopharmaceutical company focused on developing orally administered small-molecule medicines for chronic diseases. The company’s research has primarily addressed metabolic and neurological disorders, including diabetes and Alzheimer’s disease. vTv’s development portfolio has included cadisegliatin (also known as TTP399), an oral, liver-selective glucokinase activator being studied as a potential treatment for type 1 diabetes, and azeliragon, an investigational drug designed to inhibit the receptor for advanced glycation end products (RAGE) in Alzheimer’s disease. The company has also investigated other compounds targeting metabolic pathways, including oral treatments that may influence glucose regulation and appetite. Based in the United States, vTv conducts development activities through clinical research and collaborations intended to advance its drug candidates toward potential commercialization. Its products remain investigational and are subject to clinical testing and regulatory review; the company does not currently market an approved therapy.View vTv Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueMicrosoft Is Almost Back to $555—Now the Hard Part BeginsSkydance Just Became a Media Giant—With an $80 Billion Debt Load Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
